Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cancer Research UK picks Jones to replace Lane

This article was originally published in Scrip

Executive Summary

Cancer Research UK has appointed Professor Nic Jones Chief Scientist as from 1 February 2011. Professor Jones, currently Director of Cancer Research UK's Paterson Institute within the University of Manchester, is succeeding Professor Sir David Lane, who is currently leading a pioneering research team in Singapore and will continue to advise the charity on its research strategy as an ongoing member of its scientific strategy advisory group. Professor Jones will step down as the Paterson Institute's Director but will continue to lead his research group at the Paterson which studies how cells respond to sudden adverse changes in their surroundings, known as 'environmental stress'. He will also continue in his role as Director of the Manchester Cancer Research Centre

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC011162

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel